Malformations of cortical development (MCDs) constitute an important cause of seizures in children and often form the underlying basis for many of the epilepsy syndromes found in childhood. Functional neuroimaging with positron emission tomography (PET) plays a critical role in the diagnosis and management of MCDs, including cortical dysplasias, in children with drug-resistant epilepsy. In this chapter, we begin with a focused discussion on the continuing relevance of well-established PET techniques such as 2-deoxy-2[18F]fluoro-D-glucose (FDG) PET, particularly in the light of newer advances in structural imaging techniques. The limitations with these techniques are also discussed in some detail, followed by a discussion on recent advances such as quantitative imaging, hybrid PET-MRI scanners, PISCOM, and the utilization of artificial intelligence in the interpretation of these studies. Thereafter, we discuss the use and limitations of GABAA receptor imaging, and advances made by tryptophan PET imaging in cortical dysplasias and tuberous sclerosis. Finally, we conclude the chapter with a brief discussion on other promising new tracers and their likely roles in PET imaging of cortical dysplasias.